The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...

A groundbreaking study by researchers at the Queensland Brain Institute reveals that low-intensity ultrasound therapy can ...

Alzheimer’s disease is usually associated with old age. But around 5%-10% of all Alzheimer’s cases occur in people under the age of 65. Early-onset Alzheimer’s disease progresses more rapidly and ...

A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

Certain widely used drug combinations may either slow down or worsen the progression of Alzheimer's disease, but their ...

A new study has revealed that semaglutide, a widely used diabetes and weight loss drug, sold under the brand name Ozempic, ...

The company behind the drug donanemab said it will ask regulators to reconsider the decision. View on euronews ...